We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Characteristics, management and outcome of acquired amegakaryocytic thrombocytopenia.
- Authors
Roeser, Anais; Moulis, Guillaume; Ebbo, Mikael; Terriou, Louis; Poullot, Elsa; Lioger, Bertrand; Chilles, Marie; Labussière‐Wallet, Helene; Mausservey, Christelle; Pha, Micheline; Puyade, Mathieu; Cheze, Stephane; Limal, Nicolas; Michel, Marc; Godeau, Bertrand; Mahévas, Matthieu
- Abstract
Patients with AAT are often initially misdiagnosed as having immune thrombocytopenia (ITP) but do not usually respond to ITP first-line therapy (i.e. corticosteroids [CS] and intravenous immunoglobulin [IVIg]). After a median follow-up of 4.0 years (range: 1.2-11.9), two (16.7%) patients developed AA (7 and 41.5 months after AAT diagnosis), and two developed B-cell lymphoma (8 and 9 years after AAT diagnosis). Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. Amegakaryocytic thrombocytopenia is characterized by severe thrombocytopenia associated with aplastic or hypoplastic megakaryocytic lineage in the bone marrow (BM), and usually preserved granular and erythroid lineage.
- Publication
British Journal of Haematology, 2022, Vol 198, Issue 3, p595
- ISSN
0007-1048
- Publication type
Academic Journal
- DOI
10.1111/bjh.18235